1 3 0 4 VOLUME 17 | NUMBER 10 | OCTOBER 2011 nature medicine Calcineurin inhibitors (CNIs) are immunosuppressive drugs that are used widely to prevent rejection of transplanted organs and to treat autoimmune disease. Hypertension and renal tubule dysfunction, including hyperkalemia, hypercalciuria and acidosis, often complicate their use 1,2 . These side effects resemble familial hyperkalemic hypertension, a genetic disease characterized by overactivity of the renal sodium chloride cotransporter (NCC) and caused by mutations in genes encoding WNK kinases. We hypothesized that CNIs induce hypertension by stimulating NCC. In wild-type mice, the CNI tacrolimus caused salt-sensitive hypertension and increased the abundance of phosphorylated NCC and the NCC-regulatory kinases WNK3, WNK4 and SPAK. We demonstrated the functional importance of NCC in this response by showing that tacrolimus did not affect blood pressure in NCC-knockout mice, whereas the hypertensive response to tacrolimus was exaggerated in mice overexpressing NCC. Moreover, hydrochlorothiazide, an NCC-blocking drug, reversed tacrolimus-induced hypertension. These observations were extended to humans by showing that kidney transplant recipients treated with tacrolimus had a greater fractional chloride excretion in response to bendroflumethiazide, another NCC-blocking drug, than individuals not treated with tacrolimus; renal NCC abundance was also greater. Together, these findings indicate that tacrolimus-induced chronic hypertension is mediated largely by NCC activation, and suggest that inexpensive and well-tolerated thiazide diuretics may be especially effective in preventing the complications of CNI treatment.
Calcineurin inhibitors (CNIs) are immunosuppressive drugs that are used widely to prevent rejection of transplanted organs and to treat autoimmune disease. Hypertension and renal tubule dysfunction, including hyperkalemia, hypercalciuria and acidosis, often complicate their use 1, 2 . These side effects resemble familial hyperkalemic hypertension, a genetic disease characterized by overactivity of the renal sodium chloride cotransporter (NCC) and caused by mutations in genes encoding WNK kinases. We hypothesized that CNIs induce hypertension by stimulating NCC. In wild-type mice, the CNI tacrolimus caused salt-sensitive hypertension and increased the abundance of phosphorylated NCC and the NCC-regulatory kinases WNK3, WNK4 and SPAK. We demonstrated the functional importance of NCC in this response by showing that tacrolimus did not affect blood pressure in NCC-knockout mice, whereas the hypertensive response to tacrolimus was exaggerated in mice overexpressing NCC. Moreover, hydrochlorothiazide, an NCC-blocking drug, reversed tacrolimus-induced hypertension. These observations were extended to humans by showing that kidney transplant recipients treated with tacrolimus had a greater fractional chloride excretion in response to bendroflumethiazide, another NCC-blocking drug, than individuals not treated with tacrolimus; renal NCC abundance was also greater. Together, these findings indicate that tacrolimus-induced chronic hypertension is mediated largely by NCC activation, and suggest that inexpensive and well-tolerated thiazide diuretics may be especially effective in preventing the complications of CNI treatment.
We first studied whether tacrolimus was capable of inducing a familial hyperkalemic hypertension (FHHt)-like phenotype in wild-type mice, as most previous studies have used rats [3] [4] [5] . Two weeks of tacrolimus administration increased systolic blood pressure (SBP) from 123 ± 3 to 145 ± 3 mm Hg ( Fig. 1a ) and caused renal sodium ( Fig. 1b) and potassium retention (Fig. 1c) , as found previously 3, 4, 6 . A transient SBP rise in both groups on days 1 and 2 was attributable to acclimation to the injections. Although higher SBPs were already present during the first week of treatment with tacrolimus, hypertension did not develop fully until the second week ( Fig. 1a) and was preceded by a decline in urinary sodium excretion (Fig. 1b) . The increase in SBP also correlated with the degree of renal sodium retention ( Fig. 1d) . Although reduced food intake with tacrolimus might also explain lower urinary sodium excretion, there was no weight loss in the tacrolimus group, and body weights in the tacrolimus and vehicle-treated mice were similar. In a separate group of mice, we showed that tacrolimus-induced hypertension was salt-sensitive ( Fig. 1e) . Tacrolimus caused a modest increase in plasma aldosterone concentration ( Fig. 1f) , but it is unlikely that this is the main factor causing hypertension. Hypertension was more severe in tacrolimus-treated mice on a high sodium diet ( Fig. 1e) , during which plasma aldosterone concentration was suppressed ( Fig. 1f) , than it was on a normal salt diet. To confirm that the modest rise in plasma aldosterone to 348 ± 20 pg ml −1 during tacrolimus treatment was not responsible for the rise in SBP, we infused additional mice with aldosterone for 2 weeks, without tacrolimus. This treatment increased plasma aldosterone concentrations to 1506 ± 614 pg ml −1 but did not increase SBP significantly (121 ± 6 mm Hg to 125 ± 5 mm Hg; P > 0.05). Although this result indicates that the increase in plasma aldosterone concentration is not responsible for the effect of tacrolimus on SBP, aldosterone could still have a permissive role.
In addition to hypertension, tacrolimus caused hypomagnesemia, hypercalciuria and lowered plasma bicarbonate, with a positive urine anion gap, consistent with renal tubular acidosis ( Supplementary  Table 1 ); the degree of hypercalciuria was strain-dependent ( Supplementary Fig. 1 ). Although tacrolimus did not cause frank hyperkalemia during normal potassium intake, when mice consumed high-potassium chow, blood potassium concentration was higher in tacrolimus-treated mice (5.4 ± 0.2 mmol per liter) than in vehicletreated mice (4.5 ± 0.3 mmol per liter, P = 0.02, Supplementary  Fig. 2) . These results confirm that tacrolimus causes salt-sensitive hypertension, hypercalciuria, renal tubular acidosis and potassium retention in mice, recapitulating the FHHt phenotype.
Tacrolimus interacts with several binding proteins to exert effects 7 . One of these, FKBP12 (also known as FKBP1a), is essential for its immunosuppressive effects and is widely expressed, including throughout the nephron, where it is prominent along the distal tubule 8 . CNIs inhibit calcineurin (also called protein phosphatase 3, formerly protein phosphatase 2b), a phosphatase believed to have a central role in immunosuppression. Calcineurin comprises a catalytic (A) subunit, with three closely related isoforms (α, β and γ), and a regulatory (B) subunit. Calcineurin A-α is considered to be the dominant isoform in the renal cortex 9 , where NCC is expressed 10 , and inhibition of calcineurin A-α activity is thought to be responsible for CNI nephrotoxicity 9 . We first confirmed that calcineurin A-α is expressed by cells of the distal convoluted tubule (DCT; Fig. 2a ). Next, we showed that tacrolimus treatment increased the abundance of phosphorylated (activated) NCC (pNCC; Fig. 2b ), detected using an antibody specific to phosphothreonine 53 (ref. 10); total NCC abundance was not increased. Tacrolimus treatment also decreased the abundance of the transient receptor calcium channel TRPV5 ( Fig. 2b) , consistent with a previous report that tacrolimus reduces the abundance of TRPV5 messenger RNA in rats 3 . In rats, another CNI, cyclosporine, has been shown to increase NKCC2 abundance 11 , but we did not find an effect of tacrolimus on NKCC2 in mice ( Fig. 2b) . Tacrolimus treatment did increase the abundance of WNK3, WNK4 ( Fig. 2c ) and the STE20-related kinase SPAK; it also caused a shift in the electrophoretic mobility of SPAK, indicating its activation 12 (Fig. 2c) .
As WNK3 and SPAK have been shown to increase NCC activity through effects on NCC trafficking and phosphorylation, they may be involved in tacrolimus-induced NCC activation. The increased WNK4 abundance observed in tacrolimus-treated mice seems at odds with WNK4's proposed role as a negative regulator of NCC 13 ; however, WNK4 has been shown to switch to a stimulatory form under some conditions 14 , and may also have been induced as a compensatory response. Another group recently reported that cyclosporine treatment increases WNK4 and NCC abundance in rats 15 , effects consistent with our observations. These results point to an effect of tacrolimus on the DCT, the only nephron segment expressing NCC. CNIs might increase the abundance of activated NCC directly, perhaps by inhibiting phosphate removal from the NCC amino terminus. To test for such a direct effect, in the absence of systemic factors, we determined the abundance of NCC and pNCC in stably transfected HEK293 cells. Tacrolimus treatment increased pNCC abundance in these cells ( Fig. 2d) , indicating that systemic factors are not required. Although this result is consistent with tacrolimus inhibiting calcineurin actions on NCC directly, it is also consistent with secondary activation via SPAK or WNK kinases, as HEK293 cells express these kinases endogenously (data not shown). Further work will be required to unravel these possibilities.
These results indicate that tacrolimus stimulates NCC activity in vivo and in vitro, but do not indicate whether this stimulation is responsible for the effect of tacrolimus on raising SBP. To address this issue, we analyzed the effects of tacrolimus on SBP in NCC-knockout mice and in mice overexpressing NCC. As reported previously 16 , we found that NCC-knockout mice had normal SBP under control conditions ( Fig. 3a) . Unlike wild-type mice ( Fig. 1a) , NCC-knockout mice were resistant to the effect of tacrolimus treatment in raising SBP ( Fig. 3a) . Consistent with this result, tacrolimus treatment of these mice also did not affect renal sodium, potassium and calcium excretion, or plasma bicarbonate and magnesium concentrations (Supplementary Table 2 ). The peak plasma tacrolimus concentration was similar in NCCknockout and wild-type mice (49.8 versus 46.1 ng ml −1 , determined from a pooled sample of all animals in each group), indicating that the observed differences were not the result of altered tacrolimus pharmacokinetics. Our results, based on studies in mice, support the suggestion of others on the basis of a clinical observation that NCC has an important role in tacrolimus-induced hypertension 17 : kidney transplantation from a donor with undetected Gitelman syndrome normalized blood pressure and led to hypokalemia in a hypertensive individual, despite ongoing tacrolimus treatment.
Because NCC-knockout mice lack this transporter throughout life, developmental effects due to NCC deficiency may have contributed to the resistance of these mice to tacrolimus treatment. To exclude this possibility, we showed that hypertension induced in wild-type mice by tacrolimus was reversed by treatment with hydrochlorothiazide, a pharmacological inhibitor of NCC (Fig. 3b) . A thiazide-induced natriuresis or chloriuresis is often used as a marker of NCC activity in experimental animals and humans 18, 19 . Hydrochlorothiazide caused a greater natriuresis in tacrolimus-treated mice than in untreated mice ( Fig. 3c) , supporting the conclusion that increased NCC activity mediates the effects of tacrolimus. Notably, treatment with hydrochlorothiazide for 4 d did not worsen tacrolimus-induced hypomagnesemia in wild-type mice (plasma magnesium 0.72 ± 0.03 versus 0.78 ± 0.08 mmol liter −1 ; P = 0.5), suggesting that tacrolimus treatment of humans may not exacerbate the hypomagnesemia induced by CNIs.
In as much as NCC-knockout mice were resistant to hypertension when treated with tacrolimus, we next tested the effects of tacrolimus on transgenic mice overexpressing NCC. These mice, which our group has recently generated 10 , have no overt phenotype at baseline, despite a 70% increase in total NCC abundance compared to wildtype controls; this lack of a phenotype is consistent with the lack of an increase in pNCC abundance. When treated with tacrolimus, mice overexpressing NCC developed more severe hypertension than did their wild-type counterparts (Fig. 3d) . Notably, the transgenic NCC mice and their wild-type controls had a lower baseline SBP than the mice in the previous experiments, which was attributed to a strain difference (see Online Methods), as reported elsewhere 20 . The more severe hypertension in the transgenic NCC mice receiving tacrolimus was associated with increased pNCC abundance compared to tacrolimus-treated wild-type mice (Fig. 3e,f) .
To analyze whether these findings in experimental animals extend to humans, we identified CNI-treated recipients of kidney transplants with an FHHt-like phenotype. This was defined as individuals on a CNI with resistant hypertension (requiring two or more antihypertensive agents), hyperkalemia (plasma potassium recurrently >5.5 mmol per liter) or acidosis (serum bicarbonate recurrently <20 mmol per liter, or requiring oral bicarbonate supplements); all had serum creatinine values below 150 µmol per liter (Supplementary Table 3 ). The change in fractional chloride excretion (FE Cl ) after a single dose of bendroflumethiazide was taken as a measure of NCC activity. Individuals with CNI-induced hypertension had a significantly (P = 0.003) greater change in FE Cl after bendroflumethiazide treatment Immunoblots showing effects of tacrolimus on HEK293 cells. NCC expression was undetectable when cells were not induced with tetracycline (Un). Induced cells were either untreated (0), or treated with vehicle (Veh) or with tacrolimus (Tac). Bands corresponding to total NCC were detected at ~130 kDa (*) and 110 kDa (#), indicating mature and immature forms, respectively, whereas the band corresponding to pNCC was detected only at 130 kDa. Representative immunoblots are shown. Densitometry was normalized for actin. Significance was determined by unpaired t test. NS, not significant. Error bars are means ± s.e.m. than did healthy volunteer controls ( Fig. 4a and Supplementary Table 3 ). Recipients of kidney transplants who were treated with sirolimus but not a CNI had a significantly smaller (P = 0.04) response than did CNI-treated individuals, similar to controls (Fig. 4a) . Bioimpedance measurements showed that extracellular fluid volume was expanded in the CNI group compared with controls ( Fig. 4b,c) , although there was no significant difference in plasma renin activity or plasma aldosterone concentration (Fig. 4d,e ). We examined transplant biopsy samples using immunohistochemistry for NCC and pNCC in individuals treated with CNIs with an FHHt phenotype ( Supplementary   Table 4 ) and compared them with biopsy samples from aftertransplant individuals treated with azathioprine ( Supplementary  Table 5 ), and with samples from prospective kidney donors (Supplementary Table 6 ). The subjects treated with CNIs had a pronounced increase in NCC and pNCC staining compared with the azathioprine and healthy control groups (Fig. 4f shows representative examples; the other biopsy samples are shown in Supplementary  Fig. 3) . Enhanced staining was visible in 10 of 14 biopsy samples from the CNI group but in none of 13 from the azathioprine group (P < 0.001, by Fisher's exact test). CNI-induced hypertension has been attributed to a combination of vasoconstriction and renal sodium retention 21, 22 . When administered in high doses, especially intravenously, vascular effects predominate 5 . CNIs have been shown to constrict arterioles, an effect that may be both direct and via sympathetic activation. For this reason CNI-induced hypertension is often treated with calcium channel blockers 21 . Calcium channel blockers are mainly vasodilatory drugs, although a natriuretic effect has been demonstrated for some classes 23 . Our results show that activation of the NCC in the DCT is necessary for CNIs to cause sustained hypertension. This does not, however, exclude an important role for vasoconstriction either as a direct effect or as a result of sodium retention. Changes in vasoreactivity occur in association with altered sodium balance; for example, individuals with FHHt have an enhanced response to a 'cold pressor' test 24 , whereas subjects with Gitelman syndrome have increased vasodilation 25, 26 . In Gitelman syndrome the deleted gene, SLC12A3, is expressed in renal but not vascular tissue, indicating that the vasodilation must be the result of kidney dysfunction 25 . According to Guyton's model of whole-body autoregulation, sodium retention will result in a pressure natriuresis and secondary vasoconstriction 27 . Indeed, a role for increased endothelin and reduced nitric oxide has been proposed in CNI-induced hypertension in rats, but only at very high doses (5 mg kg −1 ) 5 ; moreover, an endothelin inhibitor does not completely prevent a rise in blood pressure with tacrolimus 5 .
The prevalence of the FHHt phenotype, with hypertension, hyperkalemia and acidosis, has been reported to be as high as 16-30% in some series of patients treated with CNIs 28, 29 . Hypertension may be less common with tacrolimus compared with cyclosporine, but hyperkalemia seems to be more common 30 . A long-term follow-up study detected hyperkalemia and hypertension in approximately 33% of individuals with liver transplants maintained on tacrolimus 2 , suggesting that these complications are relatively common. Our data suggest that thiazide diuretics should be uniquely effective in treating CNIinduced hypertension and hyperkalemia. Although there are concerns about combining CNIs with thiazides because of the tendency of the latter to cause magnesium wasting and glucose intolerance 31 , our own data and a previous clinical study 32 indicate that thiazides do not worsen CNI-induced hypomagnesemia.
The contribution of CNIs to decreasing rejection rates after transplantation is undisputed, but this benefit comes at the cost of increasing rates of hypertension, which contribute to long-term kidney damage and chronic allograft nephropathy 33 . Our findings indicate that activation of the NCC has a central role in tacrolimus-induced hypertension and imply that a controlled trial of thiazide diuretics to treat CNI-induced hypertension is justified.
MeTHodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. oNLINe MeTHodS Animal studies. All animal studies were approved by Oregon Health and Science University's Animal Care and Usage Committee (A858). All mice were male littermates (12-16 weeks, 25-30 g) and were fed a normal (0.5%), high-sodium (8%) or high-potassium (5%) diet (Harlan Laboratories), as indicated. All mice had a BALB/c background, except for the transgenic mice and their wild-type controls (C57BL/6;129SV). Our NCC-knockout colony was backcrossed to BALB/c every 10 generations to maintain the genetic background. The NCC transgenic animals were recently generated by our group 10 . Standard PCR, using previously reported primers 16 , was used to distinguish NCC-knockout and transgenic mice from wild-type mice. SBPs were measured with tail-cuffs using volumetric pressure recording (CODA-6; Kent Scientific). This method has been validated for SBP measurements in mice, demonstrating excellent correlation with radiotelemetry 34, 35 . The mice were first acclimated to the experimental procedure for five consecutive days; baseline SBP was then measured for 3 d, followed by daily measurements before the tacrolimus or vehicle injections. Tacrolimus (Enzo Life Sciences) was dissolved in ethanol, Tween-20 and sterile saline; the vehicle solution contained the same concentrations of the solvents. Tacrolimus or vehicle was administered subcutaneously; the dose of tacrolimus was 1 mg per kg body weight per day.
Blood and urinary measurements in mice. Whole blood was collected via terminal cardiac puncture (under anesthesia) and immediately pipetted into an i-STAT analyzer (Abbott Point of Care). The remainder of the blood was centrifuged to measure plasma magnesium (Pointe Scientific), aldosterone (ELISA; IBL-America) and tacrolimus (~4 h after the last injection; Architect Tacrolimus Reagent Kit; Abbott Laboratories). Metabolic cages were used for collection of spot urine and 24-h urine (under mineral oil); water and food were provided as gel to avoid dilution of urine with drinking water. A 3-h timed urine collection was used for the thiazide response; before this procedure, the animals' bladders were emptied by bladder massage. Urine sodium and potassium concentrations were measured using a dual-channel flame photometer (Cole-Palmer Instrument). Urine chloride, calcium and creatinine were measured using the mercuric thiocyanate, cresolphthalein complexone and modified Jaffé methods, respectively (all from Pointe Scientific).
Generation and culture of human embryonic kidney 293 cells transfected with NCC. Complementary DNA (cDNA) encoding full-length mouse NCC was subcloned into the pcDNA5/FRT/TO vector (Invitrogen). Flp-In 293 host cells (Invitrogen) were cotransfected with the pcDNA5/FRT/TO-NCC construct and pOG44, a plasmid expressing Flp recombinase, resulting in a homologous recombination event. Transfected cells were screened for hygromycin resistance and lack of β-galactosidase activity. The Flp-In T-REx 293 NCC cell line was maintained in high-glucose DMEM containing 10% v/v FBS, 200 µg ml −1 hygromycin, 15 µg ml −1 blasticidin and penicillin/streptomycin. NCC induction was confirmed by incubating the cells with or without tetracycline (1 µg ml −1 ), followed by cell lysis and immunoblotting with antibodies specific to NCC and to pNCC.
Human studies. All human studies were approved by the West London Ethics Committee 3, and indivudals gave informed consent for all procedures. Kidney transplant recipients on tacrolimus (all outpatients) were selected with at least two out of three features of the following: resistant hypertension, otherwise unexplained metabolic acidosis or hyperkalemia. They were compared with kidney transplant recipients using sirolimus, azathioprine and with untreated healthy volunteers, as indicated in the Figures. The thiazide sensitivity test was based on one previously described 18 . Urine and plasma electrolytes were measured by ion-selective electrodes, and creatinine by the compensated kinetic Jaffé method (Roche). Plasma renin activity and plasma aldosterone concentration were measured by radioimmunoassay (Diasorin and Siemens). Multifrequency bioelectrical impedance analysis was performed using a tetrapolar eight-point tactile electrode system (Inbody720; Biospace).
Immunoblotting. Mouse kidneys were harvested and snap-frozen in liquid nitrogen. Kidneys were then homogenized on ice in chilled homogenization buffer containing protease and phosphatase inhibitors. Protein (20-80 µg) was separated on 3-8% (wt/vol) Tris acetate gel (Invitrogen) as described 36 . All primary antibodies had been characterized and were specific to the following proteins: NCC, pNCC at threonine-53, WNK3 (Supplementary Fig. 4) , WNK4 (all developed in our laboratory) 10, 36 , NKCC2 and pNKCC2 (ref. 37 ), SPAK 38 and TRPV5 (Santa Cruz Biotechnology, SC-30187) 39 . Densitometry was performed using ImageJ (http://rsbweb.nih.gov/ij/).
Immunofluorescence and immunohistochemistry.
For calcineurin and NCC immunohistochemistry and immunofluorescence on mouse kidney sections ( Fig. 2a) , an untreated wild-type BALB/c mouse was perfusion-fixed with 4% (vol/vol) paraformaldehyde in phosphate buffered saline (PBS) via the abdominal aorta and cryoprotected in 800 mOsm per liter sucrose-(PBS). After freezing in liquid nitrogen, 7-µm sections were prepared on a cryostat. Sections were blocked with 5% (wt/vol) skim milk-PBS and incubated with primary antibody at 4 °C overnight, followed by incubation with Cy-3-or horseradish peroxidase-coupled secondary antibody. Secondary antibodies conjugated with horseradish peroxidase were detected using diaminobenzidine. Antibodies specific to calcineurin A-α were obtained from Santa Cruz Biotechnology (sc-6123). Human kidney sections for NCC and pNCC were stained on paraffinembedded sections using standard procedures. The sections were blocked with 1% (wt/vol) BSA in PBS and stained with antibodies specific to NCC (1:3,000, The Binding Site) and pNCC (see above). Confocal microscopy was carried out using an Olympus IX81.
Statistical analyses.
All values are expressed as mean ± s.e.m. For the animal and human studies, comparisons between two groups were done using the Student's t test (paired or unpaired, as indicated in figure legends). Multigroup comparisons were done using one-way ANOVA followed by a post hoc test. In animals, SBP data were analyzed using two-way ANOVA to assess whether the changes from average baseline SBP to final-day SBP in the two groups were different.
